Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + folic acid is a fixed-dose combination oral tablet containing the calcium channel blocker amlodipine and the water-soluble vitamin folic acid. This combination is primarily indicated for the treatment of essential hypertension, particularly in patients with hyperhomocysteinemia. Amlodipine acts as a voltage-gated calcium channel blocker, leading to vasodilation and blood pressure reduction. Folic acid participates in homocysteine metabolism, lowering plasma homocysteine levels—a risk factor for cardiovascular disease. Clinical studies have shown that this combination is more effective than amlodipine alone at reducing both blood pressure and plasma homocysteine levels, potentially offering additional protection against complications such as stroke[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + folic acid.